Assertio Therapeutics

Assertio Therapeutics est une société cotée sous le symbole boursier DEPO (US).

Voir l'organigramme avec ses 12 principaux dirigeants

Biographies les plus recherchées chez Assertio Therapeutics

• Daniel Peisert, Chief Executive Officer and Director
• Heather Mason, Director
• William McKee, Director

Créer une alerte
pour suivre les mouvements de dirigeants chez Assertio Therapeutics.

Assertio Therapeutics a 2 037 concurrents dont Pfizer (Etats—Unis), Johnson & Johnson (Etats—Unis) et Roche (Suisse).

Actualités en fusion/acquisition en Pharmacie.

• Pfizer has announced the acquisition of Biohaven Pharmaceutical  (publié le 12 mai 2022).
• Corden Pharma and Astorg Partners have announced they will merge  (publié le 4 mai 2022)..
• Hikma Pharmaceuticals a acquis Custopharm (publié le 22 avril 2022).

Contacts en Pharmacie

• Albert Bourla - Chief Executive Officer and Chairman of the Board chez Pfizer
• Joaquin Duato - Chief Executive Officer and Director chez Johnson & Johnson
• Luisa Bartorelli - Chief Patent Counsel chez Cosmo Pharmaceuticals

En savoir plus sur le secteur Pharmacie >

Derniers communiqués de presse par Assertio Therapeutics

• Assertio Holdings, Inc. - News
• Assertio Holdings, Inc. - News
• News Releases | Assertio Therapeutics, Inc.
• Assertio to Present at Cantor Virtual Global Healthcare Conference on September 16, 2020 | Assertio Therapeutics, Inc.
• Assertio Completed Merger with Zyla Life Sciences | Assertio Therapeutics, Inc.
• Assertio Therapeutics Announces First-Quarter 2020 Results | Assertio Therapeutics, Inc.
• Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus | Assertio Therapeutics, Inc.
• Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024 | Assertio Therapeutics, Inc.
• News Releases | Assertio Therapeutics, Inc.
• Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024 | Assertio Therapeutics, Inc.
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Assertio Therapeutics

• Assertio Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
• Assertio Therapeutics sur LinkedIn, Twitter & YouTube en 1-click

Contacter par email ses dirigeants dont Daniel Peisert

Appelez Assertio Therapeutics au +1 510...

Voir l'organigramme

Register to receive your alert

Signaler une erreur